Kyverna Therapeutics

We are committed to change the paradigm in the treatment of autoimmune diseases.

[Kyverna Therapeutics @Kyverna_Tx]

Today, we shared our Q4 and FY 2025 financial results, highlighting notable progress in advancing our #neuroimmunology #CARTcelltherapy franchise. We plan to present further #clinicaldata in our two lead indications at #AAN2026.

Read the full release for more details: https://t.co/QDJIw5zwLF

[Kyverna Therapeutics @Kyverna_Tx]

We will be presenting new data from our neuroimmunology franchise in stiff person syndrome and generalized myasthenia gravis at the American Academy of Neurology 2026 Annual Meeting April 18-22. We hope to see you in Chicago! Read more: https://t.co/cxhHsgq1Ig

#AAN2026 #SPS #MG

[Kyverna Therapeutics @Kyverna_Tx]

Join Kyverna at #Leerink Partners Global Healthcare Conference and #Jefferies Biotech on the Beach Summit to hear our latest company highlights. Learn more here: https://t.co/JeV7tZT9v1

[Kyverna Therapeutics @Kyverna_Tx]

We are pleased to welcome Sravan K. Emany and Andrew Miller, PhD, to our Board of Directors. Their expertise and leadership in #biotech will be instrumental as we advance towards commercialization. Read more here: https://t.co/XXvvftivUk

[Kyverna Therapeutics @Kyverna_Tx]

We are pleased to welcome Mayo Pujols as our new #CTO. His deep background in leading late-stage and commercial manufacturing for cell and gene therapies will be invaluable to Kyverna during our next phase of growth. Read more about Mr. Pujols: https://t.co/F5kT7FemqW

[Kyverna Therapeutics @Kyverna_Tx]

Our CEO, Warner Biddle, will deliver a presentation at #JPM26 that highlights our successful strategic execution in 2025 and upcoming priorities for 2026, including an anticipated BLA filing for our lead indication in #SPS, setting the stage for a transformational year ahead. Read more: https://t.co/Dgn5PVje2p

[Kyverna Therapeutics @Kyverna_Tx]

Today, we announced our financial results for Q3 2025, which demonstrate continued execution of meaningful clinical and corporate milestones to advance our #neuroimmunology #CART franchise.

Read the full release: https://t.co/1WptpkooRl

[Kyverna Therapeutics @Kyverna_Tx]

We look forward to having our CEO, Warner Biddle, participate in the upcoming Jefferies Global Healthcare Conference in London on Monday, November 17.

Learn more: https://t.co/TOKrnfHCNB

[Kyverna Therapeutics @Kyverna_Tx]

We have closed a loan facility for up to $150 million with Oxford Finance, which will strengthen our financial flexibility and support the advancement of our late-stage indications in #MG and #SPS.

Read more here: https://t.co/xzliV8Nzm6

[Kyverna Therapeutics @Kyverna_Tx]

We will present positive interim data from the Phase 2 portion of our registrational KYSA-6 trial with our investigational CAR T-cell therapy, KYV-101, in generalized #MG today at @AANEMorg.

Read more: https://t.co/bP7p8PHklu

[Kyverna Therapeutics @Kyverna_Tx]

We are excited to share that new data from the Phase 1 portion of an investigator-initiated Phase 1/2 trial in #RheumatoidArthritis will be presented at @ACRheum Convergence 2025.

Find more details in our latest release: https://t.co/VqD3tdezcM

#ACR25

[Kyverna Therapeutics @Kyverna_Tx]

Join us next week on Wednesday 10/29 for an IR conference call where we will be discussing interim data from the KYSA-6 Phase 2 clinical trial investigating KYV-101 in #MG.

Details on how to register can be found here: https://t.co/0ZOSKuare8

[Kyverna Therapeutics @Kyverna_Tx]

We were proud to support @MyastheniaOrg at the MG Walk in SoCal and Community Health Fair in Houston. Thank you for the opportunity to educate patients, caregivers, and advocates about Kyverna's CAR T-cell therapies.

#MGCommunity #MGFA #AutoimmuneAwareness #PatientAdvocacy

[Kyverna Therapeutics @Kyverna_Tx]

We’re looking forward to next week’s Cell & Gene Meeting on the Mesa to share the latest developments in advancing CAR T-cell therapy for autoimmune diseases. Find Kyverna in Phoenix: https://t.co/pspbK2F8Qt

#CGMesa25 #MeetingontheMesa #CARTcelltherapy

[Kyverna Therapeutics @Kyverna_Tx]

Join us in spreading the word about our #MyastheniaGravis Phase 3 clinical trial, KYSA-6. If you or someone you know is affected by MG, learn more at https://t.co/EE0I1XEvxf

#CARTcelltherapy #neuroimmunology #MG